NEW YORK – Boston-based NanoView Biosciences said today that it has signed an exclusive agreement with Alfatest, headquartered in Rome, to distribute its ExoView platform in Italy.
The research-use-only ExoView platform is an antibody labeling and imaging-based extracellular vesicle detection system that provides size analysis, vesicle count, phenotyping, and biomarker colocalization. According to the company, it requires minimal sample input, no sample prep or purification, and can be used directly with complex biological samples.
NanoView CEO Jerry Williamson said in a statement that the deal reflects his firm's push to expand global access to the ExoView and to "accelerate exosome research around the world."
In addition to the new deal with Alfatest, NanoView has an agreement with Quantum Design International, announced in April, for distribution of the platform in Japan.